A new study, conducted by Justin Lathia, PhD, co-leader of Case CCC's Molecular Oncology Program, and published in the journal Nature Cancer, is the topic of conversation in the most recent issue of the NIH Director's Blog.
According to Lawrence Tabak, DDS, PhD, acting director of the National Institutes of Health (NIH), while more study is needed to confirm the study's recommendations in people with glioblastoma, the findings are an important reminder that treatment advances in oncology may come not only from the study of the cancer itself but also by carefully considering the larger context and environments in which tumors grow. The hope is that these intriguing new findings will one day lead to new treatment options for the approximately 13,000 people in the U.S. alone who are diagnosed with glioblastoma each year.